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1. Introduction 
The recent establishment of in vitro cultures of human embryonic stem cells (hESC) from 
preimplantation embryos has provided a biologically relevant in vitro model for studying 
early human embryonic development and the signals involved in early stages of cellular 
commitment to different lineages. In addition, hESC represent a good source of an unlimited 
supply of cells that can generate clinical-grade, transplantable, lineage-specific cells to treat a 
large number of skeletal diseases including bone and cartilage diseases (e.g. localized bone 
and cartilage defects, non-healing fractures and systemic age-related degenerative 
conditions such as osteoporosis and osteoarthritis) (for review, [1], [2]). Typically, the basic 
in vitro methods for differentiating hESC into specific cell lineages are based on three 
procedures; 1) direct differentiation as a monolayer on extracellular matrix substrates, 2) 
differentiation in co-culture with primary tissue derived cells, and 3) the formation of 3-D 
spherical structures in suspension culture, termed embryoid bodies (EBs) [3-6]. However, 
developing clinically relevant protocols for directing the differentiation of hESC into 
definitive, homogenous populations of osteogenic or chondrogenic cells still faces several 
challenges due to the complexity of pathways that are conserved between embryonic and 
hESC differentiation for all cell types of the three germ layers. Our group, and others, have 
employed several strategies to first, generate mesenchymal progenitor cells (termed MSC) 
from hESCs demonstrating the characteristic phenotype of adult bone marrow-derived 
mesenchymal stem cells (BM-MSC), and second differentiate these cells into homogenous 
populations of osteoblast or chondrocytes by using protocols established for adult MSC. 
Thus, our objective in this chapter is to provide an overview on the majority of published 
protocols for derivation of osteoblasts and chondrocytes from hESC through an 
intermediate mesenchymal progenitor lineage.  
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2. Differentiation of hESC into mesenchymal progenitor cells 
Multipotential mesenchymal stem/stromal cells (MSCs) have been isolated from diverse 
tissues including bone marrow (BM), adipose, muscle, periodontal ligament, umbilical cord 
blood and other connective tissues. MSCs are typically characterized by their adherance to 
plastic culture plates, expression of Stro-1, CD29, CD73, CD90, CD105, CD106, CD166, 
CD146, and CD44, lack of hematopoietic markers and MHC class II expression, and ability 
to differentiate into cells of mesenchymal origin such as bone, cartilage and adipose tissue 
[7]. MSC have documented evidence for their potential use in cell-based therapy for the 
treatment of bone and cartilage defects [8].  
Derivation of MSC-like cells from hESC has previously been reported using a number of 
different approaches including direct differentiation employing withdrawal of feeders, 
addition of PDGF, or isolation and culture of spontaneous differentiation [9-13]; through an 
intermediate EB formation [14-16]; or by co-culturing hESC with primary bone derived cells  
[17], OP9 cells [18] or periodontal ligament fibroblasts [19]. In addition, methods were utilised 
for isolation of mesenchymal-like populations, based on cell sorting, employing a number of 
CD marker combinations: CD13+/-, CD71+, CD105+ [20] and CD105+, CD24- [21].  
Culturing hESC as hEBs activates well-conserved cascades of genes that govern the earliest 
events during gastrulation and germ layer formation [5] that may be important for 
subsequent differentiation. Previous publications from mouse [22] and human [23] ESCs 
have shown that early mesoderm markers are expressed during hEB formation. 
EB formation of hESC is initiated by enzymatic dissociation of hESC colonies into small 
clumps and differentiation is initiated by removal of bFGF and 2-mercaptoethanol, as well 
as by culturing the dissociated cells in ultra low adhesion culture dishes [24-26]. The length 
of time of EB culture is dependent upon the ultimate target cell type and EB differentiation 
appears to correlate well with post-implantation development of embryos [5].  
Our profiling of these cells during 20 days of EB differentiation has confirmed up-regulation 
of several mesoderm specific markers MEOX1, MIXL1, ALX4, TBX6 and FOXF1 in 
association with increasing percentages of cells expressing MSC markers including CD29, 
CD44, CD63, CD73 and CD166 (fig. 1) [27].  Thus, differentiation of hESC via EB formation 
represents a promising method for directing the hESC not only to the mesoderm lineage but 
also to mesenchymal progenitor cells.  
Since, TGFβ/BMP signaling pathways have been shown to play a role in mesoderm 
induction in vertebrates [28-30], we studied the effect of several members of the TGFβ/BMP 
family on mesoderm induction and derivation of MSC in the hESC-EBs model. We 
succeeded in developing  clinically relevant protocols for generating MSC from hESC by 
blocking TGF-ǃ signaling during hEB formation using SB-431542 (an inhibitor of activin 
receptor-like kinase (ALK)5, 4 and 7 (the TGF-ǃ type I receptor) [27]. This led to selective up-
regulation of several markers involved in mesoderm induction and myogenic differentiation 
including, TBX6 and Myf5 genes, additionally, these findings were confirmed by microarray 
analysis. In another study, we showed that the treatment of hESC-derived EBs with 
50ng/ml  Activin B (member of TGFb superfamily) for 10 days was sufficient to up-regulate 
several mesoderm specific markers (FOXF1, VE-cadherin, KDR) [31]. Further enrichment for 
MSC population was performed by establishing monolayer outgrowth culture from hEBs 
induced either by Activin B- or SB-induced. Our data showed that this strategy is very 
efficient in obtaining a homogenous MSC population with high percentage of cells 
expressing the characteristic surface markers for bone marrow derived-MSC including 
CD44, CD146, CD166, CD63, CD166 and CD73 [31].  
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Fig. 1. FACS analysis of the MSC characteristic CD marker expression in hESC during their 
spontaneous differentiation as hEBs at day 10 and 15. The percentage of positive cells is 
indicated for each graph 
3. Differentiation of hESC into chondrogenic lineages 
Embryonic chondrogenesis is a complex biological process that plays essential roles in 
endochondral ossification and skeletal patterning. It involves migration of committed 
mesenchymal cells from the cranial neural crest, paraxial mesoderm and lateral plate 
mesoderm to the site of skeletogenesis to form cell mass condensations that define the 
morphology of the future bone [32, 33]. Inside these condensations, mesenchymal cells are 
differentiated into chondrocytes that proliferate and secrete an increasing amount of 
cartilage matrix macromolecules. Chondrogenesis is terminated through chondrocyte 
hypertrophy and apoptosis and is followed by blood vessel invasion and bone matrix 
formation by osteoblasts.  
Current protocols for differentiating hESC into the chondrogenic lineage are principally 
based on differentiating hESC into the mesoderm/mesenchyme lineage via hEBs formation. 
This is followed by induction towards chondrogenesis using pellet micromass culture in 
combination with:TGFǃ1, TGFǃ3  BMP-2 and -4 [18, 31, 34], bovine chondrocyte conditioned 
medium [14] or via encapsulation in hydrogels [35], or arginine-glycine-aspartate (RGD)-
modified PEGDA hydrogels [36]. Other published strategies include, co-culture of hESC-
derived MSC with primary chondroprogenitor cells [37] and  co-culture of enriched 
mesodermal cell populations (CD73+) with murine OP9 cells [18]. However, most of these 
protocols failed to generate clinically compliant homogenous populations of chondrocytes 
that could be utilized for cartilage repair due either to their complexity or use of animal 
products such as fetal calf serum. Table 1 provides an overview on published chondrogenic 
differentiation protocols for hESC.  
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Initial  
Differentiation 
Chondrogenic 
Differentiation 
In vitro 
Analysis 
In Vivo 
experiments 
Ref 
hESC were cultured as 
EBs for  10days followed 
by outgrowth culture on 
fibronectin coated plates 
in DMEM+15%KSR+ 
50ng/ml Activin B for 
mesoderm induction. 
MSC-like cells were FACS 
sorted based of expressing 
Dlk1/FA1+. 
Pellet micromass culture 
of dlk1/FA1+cells 
induced in CDM 
medium supplemented 
with 100 nM 
Dex+50ug/ml 
VitC+1%ITS+ 10 ng/ml 
TGFǃ1. 
-FACS analysis 
for MSC 
markers. 
-Alcian blue 
staining. 
-Real-time PCR 
n/a [31] 
hESC were cultured as 
EBs for  10days followed 
by outgrowth culture on 
gelatine coated plates and 
subculturing at high 
density in DMEM+10% 
FBS to obtain MSC-like 
cells. 
hESC-MSC induced in 
Argininge-glycine-
aspartic acid (RGD)-
modified PEG-based 
hydrogels in bovine 
chondrocyte 
conditioned media: 
DMEM 10% FBS + 1µm 
dex, 200µm Indometh, 
10µg/ml insulin, 0.5mM 
IBMX  
-Immune-
staining for Col 
type 2. 
-Real-time PCR 
 
-hESC-MSC 
encapsulated in 
PEGDA 
hydrogels and 
implanted s.c. 
in athymic 
mice. 
-Cartilage 
repair capacity 
of hESC-MSC 
pellets was 
evaluated in rat 
knee defect 
model. 
[14] 
hESC were plated on 
mouse stromal OP9 cells 
in ǂMEM with  20% FBS, 
followed by FACS sorting 
of  CD73+cells to obtain 
MSC-like cells. 
Pellet micromass culture 
induced in DMEM with 
10ng/ml TGFǃ3+200µm 
Vit C in +10% FBS for 28 
days. 
-Alcian Blue 
staining. 
-Real-time PCR  
n/a [18] 
hESC were cultured as EB 
for 5 days in DMEM/F12 
+10%  FBS, trypsinised 
and plated for outgrowth 
culture. 
Cells induced in co-
culture with human 
primary chondrocytes in 
DMEM + 10%FBS, 
+1mM L-Glut + 
50µg/ml Vit C for 
28days. 
-Alcian Blue 
staining. 
-Immune-
staining for Col 
type 2 and SOX9
 
Co-culture 
hESC seeded 
onto PDLLA 
foam and 
implanted s.c. 
in SCID mice 
for 35 days. 
 
[16] 
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hESC were cultured as EB 
for 10 days and plated on 
gelatine coated plates in 
DMEM 10% FBS. 
Pellet micromass 
cultures induced in 
DMEM +1mM L-glut, 
100nm Dex+ 50µg/ml 
Vit C+ 1mM Na 
pyruvate + 1% ITS with 
10ng/ml TGFǃ1 or 
25ng/ml BMP2 for 2 
weeks . 
-Safranin o –
staining . 
-PCR  
n/a [36] 
Undifferentiated hESC 
cells were co-cultured 
with irradiated neonatal 
or adult articular 
chondrocytes in high-
density pellet mass 
cultures for 14 days, 
followed by monolayer 
expansion. 
-Pellet micromass 
cultures of co cultured 
hESC  were induced in 
DMEM with 10%FCS 
and 10ng/ml TGFǃ3.  
-Co-cultures induced in 
hyaluronan-based 
Hyaff-11 scaffolds  
-Safranin o –and 
Alcian Blue 
staining  
n/a [44] 
hESC were cultured as 
EBs for 5 days in DMEM 
+10%  FBS. Single cells 
were obtained either from 
the hESC aggregates or 
EBs day5. 
hESC or 5-day EB-
derived cells were 
resuspended 
at a high density  
in DMEM + ITS, 
1.25mg/ml BSA+ 
5.35µg/ml linoleic acid, 
1% KSR+ 40µg/ml L-
proline, 50µg/ml Vit C, 
1% NEAA, 100nM 
Dex+100ng/ml BMP2  
and cultured in 
micromass on gelatin 
coated  plates. 
-Immune-
staining for Col 
type 2. 
n/a [45] 
Dissociated single human 
ESCs were cultured and 
passaged on gelatin-
coated plates in DMEM + 
10% FBS, 5ng/ml FGF2.  
 
Pellet micromass culture 
of hESC aggregates  
induced in  DMEM + 
0.1µM dex+ 50µM Vit 
C+ 40µg/ml proline, 
1mM Na pyruvate+ 1% 
ITS+ premix, and/or 
10ng/ml TGFǃ1 or 
300ng/ml BMP7 for 
14days. 
-Toluidine blue 
staining,  
-Col type 2 
staining 
-RT-PCR 
n/a [46] 
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Used the same protocol as 
[45] 
 
 
 
 
 
 
Used the same protocol 
as [45] except used 
10ng/ml of TGFǃ1 or 1 
μM SB431542 instead of 
BMP2 in chondrogenic 
media to study the effect 
of TGFǃ signaling 
pathway. 
Real-time PCR 
Col2 immune-
staining 
n/a [47] 
hESC were cultured on Matrigel and differentiated 
as EBs in chondrogenic media consisting of DMEM 
with 100nM Dex+1% ITS+ 40 μg/ml L-proline, 50 
μg/ml VitC+ 100 μg/ml sodium pyruvate and 1 
ng/ml TGFǃ1. EBs were cultured in this medium 
for 3 weeks. 
col1, 2 and GAG 
staining. 
Mechanical 
testing using 
unconfined creep 
cytocompression
n/a [48] 
Abbreviations used, EB: embryoid bodies; KSR:knockout serum replacement; FBS :fetal bovine serum; 
CDM: chemically defined medium; Dex: dexamethasone; VitC: ascorbic acid/vitamin C; RGD: arginine-
glycine-aspartic acid; PEG: poly ethylene glycol; Indometh: indomethacin; IBMX: 3-isobutyl-1-
methylxanthine; NEAA: non essential amino acids; PEGDA: Poly (Ethylene Glycol)-Diacrylate; s.c: 
subcutaneously; PDLLA: Poly-DL-lactic acid 
Table 1. hESC chondrogenic differentiation protocols 
We have recently identified dlk1/FA1 as a surface marker for chondrogenesis that indicates 
transition of immature proliferating to pre-mature hypertrophic chondrocytes during mouse 
embryonic limb development as well as in vivo hESC-derived teratoma formation.  Our data 
showed that Dlk1 is a dynamic surface marker and responds to some external stimuli 
controlling chondrogenesis.  dlk1/FA1 (delta-like 1 protein, fetal antigen 1, also named 
preadipocyte factor 1 [Pref-1]) is a membrane-associated protein belonging to 
Notch/Serrata/Delta family [38]. Dlk1/FA1 plays an important role in controlling the cell 
fate decisions during embryogenesis [39] and extends its function to regulate many 
mesoderm differentiation processes in the post-natal organism including adipogenesis [40], 
myogenesis [41] and osteoblastogenesis [42].  
We have designed a clinically relevant protocol for directing the differentiation of hESC into 
the definitive early chondrogenic lineage based on tracking the expression of dlk1/FA1 as a 
mesoderm/chondroprogenitor surface marker. In this protocol, treatment of hESC-EB 
cultures with Activin B is shown to markedly up-regulate dlk1/FA1 expression in 
association with increasing several mesoderm induction markers (i.e. FOXF1, KDR and 
MEOX1) [31]. By establishing an hEB-outgrowth culture we were able to enrich for cells 
expressing Dlk1/FA1 and obtain a homogenous population of 
mesenchymal/chondroprogenitor cells that could be further differentiated as micromass 
cultures into chondrocytes in serum free medium containing TGFǃ1 [31]. Thus, there is a 
need to identify novel surface markers that define early stages of hESC commitment to 
chondrocytes. Tracking these markers during the progression of hESC-EBs formation will be 
valuable for developing well-defined and efficient protocols for directing hESC 
differentiation into the chondrogenic lineage in vitro.  
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4. Differentiation of hESC into osteogenic lineages 
Osteoblasts originate from mesenchymal stem cells in bone marrow through a 
differentiation process that is controlled by numerous hormones and growth factors. 
Osteoblasts are characterized by expressing various phenotypic markers such as high 
alkaline phosphatase (ALP) activity and synthesizing collagenous and noncollagenous bone 
matrix proteins including osteocalcin. The most important function of osteoblasts is to form 
mineralized bone [43]. 
 
Initial  
Differentiation 
Osteogenic 
 Induction 
In vitro 
assays 
In Vivo  
assays 
Ref 
hESC were cultured as 
EBs for  10days followed 
by outgrowth culture on 
fibronectin coated plates 
in DMEM+15%KSR+ 10 
μM SB421543. hEBs-
outgrowth were 
passaged and 
maintained in CDM 
medium for enrichment 
for MSC. 
hESC-MSC induced in 
ǂMEM medium with 
10%FCS+10mM ǃ-glyc+ 
100µg/ml Vit C for 20 
days. 
-FACS 
analysis 
for MSC 
surface 
markers. 
-Alzarin 
Red and 
ALP 
staining. 
-Real-time 
PCR. 
hESC-MSC  were 
mixed with HA/TCP 
s.c. into Nod/SCID 
mice for 8 weeks. 
[27] 
hESC were cultured as 
EBs for 10 days and 
plated for outgrowth 
culture on gelatine 
coated plates in 
DMEM+10% FBS+2mM 
L-Glut to obtain MSC-
like cells. 
hESC-MSC induced in 
DMEM media with 50µM 
Vit C + 10mM ǃ-glyc + 
100nM Dex in for 14 d 
-Alzarin 
Red and 
ALP 
staining. 
-Real-time 
PCR. 
hESC-MSC were 
seeded onto the 
polymer scaffold of 
PLLA/PLGA, 
cultured for 10 days 
and implanted s.c. in 
athymic mice for 8 
weeks.  
[14] 
hESC were plated on 
mouse stromal OP9 cells 
in ǂMEM with  20% FBS, 
followed by FACS 
sorting of  CD73+cells. 
CD73+cells induced in 
ǂMEM medium with 10% 
FBS+10mM ǃ-glyc+ 0.1µM 
Dex+ 200µM Vit C for 3 to 
4weeks. 
-Alzarin 
Red and -
Von Kossa 
staining. 
-Real-time 
PCR. 
n/a [18] 
hESC were cultured as 
EBs for 3 to 4 days, 
trypsinised and plated 
onto gelatin plates in 
KODMEM + 10% FBS, L-
Glut, NEAA, BME 
Cells induced in 
KODMEM + 10% FBS+ 
BME +50µM Vit C, 10mM 
ǃ-glyc +100nM Dex 
-Von 
Kossa 
staining  
Cells induced for 4d, 
injected into 
diffusion chamber 
and implanted into 
nude mice for 7 
weeks.  
[15] 
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hESC were cultured as 
EBs for 7 days,  and 
plated onto gelatin 
coated plates in ǂMEM 
with 10% FBS+ 200mM 
L-glut+10mM 
NEAA+4ng/ml FGF for 
up to 2 weeks.  
hESC-MSC were induced 
as described [18] 
-Von 
Kossa 
staining 
n/a [49] 
hEBs day3 were plated 
with inactivated human 
primary bone derived 
cells (hPBDs). 
The co-culture of hEBs-
derived cells with hPBDs 
was continued for 2 
weeks. 
-Real Time 
PCR 
Cells seeded on 
PLGA/HA scaffolds 
implanted with 
BMP2 s.c. into SCID 
mice for 4 & 8 weeks.  
[17] 
Removal of MSC-like 
cells from long term 
culture of hESC colonies 
in feeder free system. 
hESC-MSC induced in 
ǂMEM with 20% FBS 
+10nM Dex+ 0.2 mM 
VitC+ 10 mM +ǃ-glyc for 3 
weeks 
-Alzarin 
Red 
staining. 
 
n/a [20] 
hESC aggregates were 
removed from the MEF 
and placed onto a tissue 
culture dish for 24 hours, 
followed by single-cell 
suspensions and 
subsequent plating. 
Cells were induced in 
aMEM with FBS was 
supplemented with 10nM 
DEX+ 50µg/ml 
VitC + 5 mM ǃ-glyc 
-Von 
Kossa and 
ALP 
staining . 
n/a [50] 
hESC single cell 
suspension plated on 
gelatin coated plate in 
DMEM-HG, L-Glut+ 
10% FBS+ 10ng/ml FGF. 
Continuous passaging to 
obtain hESC-MSC. 
hESC-MSC induced in 
DMEM + 1% PEST, L-
glutamine (2mM), 10% 
FCS+ 45 nM VitC+ 100nM 
dex+ 20mM ǃ-glyc  
 for 6 weeks. 
-Von 
Kossa 
staining 
 
n/a [51] 
hESC were cultured as 
EBs for 10 days,  and 
plated onto gelatin plates 
in aMEM + 20% FBS, 
NEAA, L-Glut, 1ng/ml 
FGF. hESC-MSC 
outgrowth cells taken to 
p4 
hESC-MSC induced in 
DMEM, 10%FBS, 50 
μg/mL Vit C, 10mM ǃ-
glyc +100nM Dex or 
50ng/ml BMP7 or 
Dex+BMP7 for 4 weeks. 
Cells induced also on 
Scaffolds (6 weeks), 
matrices or film cultured 
with Dex+BMP7. 
-Von 
Kossa and 
ALP 
staining 
n/a [52] 
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hESC were cultured as 
EBs for 5 days in 
DMEM/F12, 10% KSR, 
NEAA, BME. EBs were 
placed on Matrigel 
coated plated .  
Attached EBs were 
induced in medium with 
0.1 mM VitC+ 10mM ǃ-
glyc, 0.1 mM dex +/- 5µM 
LY294002+ 0.5µM AKT 
inhibitor,+1nM 
Rapamycin or 10nM 
FK506 (PI3K/AKT/mTOR 
inhibitors) for 3 weeks. 
-Von 
Kossa and 
ALP 
staining. 
-Real time-
PCR. 
n/a [53] 
Prolonged in 
vitro cultivation and 
starvation for hESC 
mesenchymal 
differentiation based on 
method used by [20]. 
Medias: 
#1 KODMEM + 20% KSR, 
with/without FBS (hi or 
non hi) or 5% hPL + 
40u/ml heparin; + 1% 
ITS+, and/or 10-8 M Dex, 
and 10-4 M L-ascorbic acid 
phosphate magnesium 
salt n-hydrate (AscP). 32-
45days 
#2 aMEM +10% FBS +/- 
Dex/AscP 45-69days 
#3 KODMEDM + 20 KSR, 
+/- FGF or media #2, 53 
days 
-Real time-
PCR. 
Differentiated hESC 
using different 
cocktails were mixed 
with HA/TCP and 
implanted s.c. in 
immunodeficient 
mice.  
[54] 
Abbreviations used, ǃ-glyc: beta glycerophosphate; KODMEM: Knockout DMEM; BME: BME amino 
acids; HA/TCP: Hydroxyapatite tri calcium phosphate; hi: heat inactivated 
Table 2. hESC osteogenic differentiation protocols 
A number of cell culture conditions have been used to induce differentiation of hESCs into 
the osteogenic lineage with and without EB formation. Osteoblastic differentiation of hESCs 
has principally been achieved by differentiating hESC into MSC-like cells followed by 
induction of the hESC-MSC to the osteogenic lineage using a well known osteogenic cocktail 
containing ascorbic acid, ǃ-glycerophosphate, and dexamethasone, or through co-culture 
with primary bone derived cells (more detailed protocols are shown in table 2). However, 
the majority of these protocols still show some limitations in providing homogeneous cell 
populations which are efficient in differentiating into osteoblasts and could be used in tissue 
engineering for skeletal regeneration. These limitations include; 1) insufficient data 
comparing the phenotype of hESC-derived osteoblasts with well-established osteoblastic 
cells; 2) using in vitro assays as the main criteria for evaluation of the osteogenic 
differentiation protocols; 3) small numbers of published in vivo studies examining the 
capacity of hESC-derived osteoblasts for bone regeneration; 4) little or no available data on 
the reproducibility of a specific protocol on different hESC cell lines.  
Recently, we have reported an efficient protocol for directing hESC into mesenchymal osteo-
progenitors by inhibiting TGF-β signaling with SB-431542 (SB) during hEBs formation. 
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Detailed cellular and molecular analysis revealed the differentiation of SB-treated hEBs into 
muscle progenitor cells (MPC)[27]. Successive outgrowth cultures of the MCP, in the 
presence of 10% fetal bovine serum (FBS), demonstrated a step-wise progression from a 
heterogeneous EB outgrowth cell population, through an MCP population, to a 
homogeneous population of mesenchymal progenitors that expressed CD markers 
characteristic of mesenchymal stem cells (MSCs): CD44 (100%), CD73 (98%), CD146 (96%), 
and CD166 (88%). Lastly these mesenchymal progenitors verified their ability to 
differentiate into osteoblasts in vitro and could form ectopic bone upon subcutaneous 
implantation with hydroxyl-apatite/tricalcium phosphate ceramic powder (HA/TCP) in 
immune deficient mice [27].  
5. Conclusions 
Due to the unlimited self-renewal and differentiation capacity of hESC-MSC over adult MSC 
the derivation of MSC from hESC for skeletal regeneration demonstrates a promising 
alternative to the use of adult stem cells.  Despite the increasing number of published 
protocols for differentiating hESC into definitive osteogenic and chondrogenic lineages, the 
use of hESC in tissue engineering for bone/cartilage repair in pre-clinical studies is elusive 
due to either the complexity of available protocols or lack of data on testing the functional 
activity of cells in vivo.  More work is needed, to design robust xeno-free protocols that can 
provide large numbers of homogenous and efficiently differentiated osteoblastic 
/chondrocytic cells that work on multiple hESC cell lines. To achieve this goal, new 
strategies need to be developed to improve the in vitro and in vivo assessment assays, to 
develop a predictive molecular signature for each particular cell type at different 
differentiation stages, and to identify new and dynamic surface markers that recognize early 
chondro-progenitor and osteo-progenitor cells during hESC differentiation. 
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